On the other hand, BrMSCs and/or saroglitazar treatments, initiated 14 days after pulmonary fibrosis induction, showed significantly (p < 0.05) reduced TGF-β protein levels in comparison with BLM-G. This evidence concerns the gene TGFB1 and pulmonary fibrosis.